Ebixa(Memantine hydrochloride) is used to treat Alzheimer's disease(AD). It has been commercialized in more than 60 countries since 2002. It is the only N-methyl-D-aspartate (NMDA) receptor antagonists. Ebixa is a moderate-affinity voltage-dependent uncompetitive antagonist at glutamatergic NMDA receptors. Ebixa may therefore improve cognitive function (especially for language), daily functioning and behavioral and psychiatric symptoms in AD by blocking the glutamate activity that could cause further damage to the brain cells. Ebixa is highlighted for treating behavioral and psychiatric problems, which can seriously compromise care, including aggression, agitation, aimless wandering. Ebixa can spare 52 hours to caregiver per month, which can reduce AD burden and protect nervous system.

Ebixa is used to treat moderate to severe AD. Ebixa patients were three times more likely to progress than those receiving placebo. It has little side effects, favourable tolerability and safety, the similar rate of adverse events with placebo group in long-term treatment. It has little interaction with other drug due to the pharmacological characteristics of metabolism is not via the P450 enzyme.

Ebixa provides different mechanism, unique innovation and effective response for treating dementia. Recommend as the first choice for AD treatment of the European Federation of the Neurological Societies (EFNS) guideline, 2010 Chinese guidelines for diagnosis and management of cognitive impairment and dementia, American Psychiatric Association and the National Institute for Health and Clinical Excellence. It was going public in China in 2006. There are about 1/3 patients with AD who benefits from the Ebixa application of clinical treatment in China.